World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer drugs such as b...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2017-12, Vol.21 (12), p.1211-1213 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1213 |
|---|---|
| container_issue | 12 |
| container_start_page | 1211 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 21 |
| creator | Cox, V. Furin, J. |
| description | The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer
drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals,
they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen. |
| doi_str_mv | 10.5588/ijtld.17.0199 |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_pubme</sourceid><recordid>TN_cdi_pubmed_primary_29297439</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2017/00000021/00000012/art00004</ingid><sourcerecordid>iuatld/ijtld/2017/00000021/00000012/art00004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-dfb723f72ffbd6a02cc7643ebc78caee8e47ea6ee1c0e1784e231f62c2e2f6433</originalsourceid><addsrcrecordid>eNp1ks-L1DAUx4so7g89epWCFy8d817bSetFlnV1hYVFUDyGNHmZzdA2Y34suH-96cysgmAueU0-_eSRb4riFbBV23bdO7uNo14BXzHo-yfFKXTQVrxH9jTXDHlVc-hPirMQtowhAPDnxQn22POm7k-L-x_Oj7q8JjnGu_LWb-RsH2S0bi49KTdNNOv9ZyiN8-WUxmi1T5vKU7AhyjmWMQ3kVRpdXnhfhjuXslBbY8hT3l4gLb0O5UCl3O1GS_rDi-KZkWOgl8f5vPj-6erb5XV1c_v5y-XFTaWadh0rbQaOteFozKDXkqFSfN3UNCjeKUnUUcNJrolAMQLeNYQ1mDUqJDQZrM-LtwfvzrufiUIUkw2KxlHO5FIQ0HcNNohNl9E3_6Bbl_ycuxPIILdTt9hmqjpQyrsQPBmx83aS_pcAJpZAxD4QAVwsgWT-9dGahon0H_oxgQx8PAB23uTrkn9PtUkupoMvt5CN-4FwLACF9HGpmqz5-j-NejQtz2F5DeIeYc4_Y1axDlsBLWuFJiNzuiJKLzYPIjT1bzpqu60</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014563525</pqid></control><display><type>article</type><title>World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Cox, V. ; Furin, J.</creator><creatorcontrib>Cox, V. ; Furin, J.</creatorcontrib><description>The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer
drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals,
they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.17.0199</identifier><identifier>PMID: 29297439</identifier><language>eng</language><publisher>France: International Union Against Tuberculosis and Lung Disease</publisher><subject>Antitubercular Agents - administration & dosage ; Antitubercular Agents - adverse effects ; Bedaquiline ; Delamanid ; Diarylquinolines - administration & dosage ; Diarylquinolines - adverse effects ; Drug Administration Schedule ; Drug resistance ; Drugs ; Evaluation ; Guidelines ; Humans ; Multidrug resistance ; Multidrug resistant organisms ; Nitroimidazoles - administration & dosage ; Nitroimidazoles - adverse effects ; Oxazoles - administration & dosage ; Oxazoles - adverse effects ; Practice Guidelines as Topic ; Shorter Regimen ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - microbiology ; Who ; World Health Organization</subject><ispartof>The international journal of tuberculosis and lung disease, 2017-12, Vol.21 (12), p.1211-1213</ispartof><rights>Copyright International Union against Tuberculosis and Lung Disease (IUATLD) Dec 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-dfb723f72ffbd6a02cc7643ebc78caee8e47ea6ee1c0e1784e231f62c2e2f6433</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29297439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cox, V.</creatorcontrib><creatorcontrib>Furin, J.</creatorcontrib><title>World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer
drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals,
they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen.</description><subject>Antitubercular Agents - administration & dosage</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Bedaquiline</subject><subject>Delamanid</subject><subject>Diarylquinolines - administration & dosage</subject><subject>Diarylquinolines - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug resistance</subject><subject>Drugs</subject><subject>Evaluation</subject><subject>Guidelines</subject><subject>Humans</subject><subject>Multidrug resistance</subject><subject>Multidrug resistant organisms</subject><subject>Nitroimidazoles - administration & dosage</subject><subject>Nitroimidazoles - adverse effects</subject><subject>Oxazoles - administration & dosage</subject><subject>Oxazoles - adverse effects</subject><subject>Practice Guidelines as Topic</subject><subject>Shorter Regimen</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><subject>Who</subject><subject>World Health Organization</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ks-L1DAUx4so7g89epWCFy8d817bSetFlnV1hYVFUDyGNHmZzdA2Y34suH-96cysgmAueU0-_eSRb4riFbBV23bdO7uNo14BXzHo-yfFKXTQVrxH9jTXDHlVc-hPirMQtowhAPDnxQn22POm7k-L-x_Oj7q8JjnGu_LWb-RsH2S0bi49KTdNNOv9ZyiN8-WUxmi1T5vKU7AhyjmWMQ3kVRpdXnhfhjuXslBbY8hT3l4gLb0O5UCl3O1GS_rDi-KZkWOgl8f5vPj-6erb5XV1c_v5y-XFTaWadh0rbQaOteFozKDXkqFSfN3UNCjeKUnUUcNJrolAMQLeNYQ1mDUqJDQZrM-LtwfvzrufiUIUkw2KxlHO5FIQ0HcNNohNl9E3_6Bbl_ycuxPIILdTt9hmqjpQyrsQPBmx83aS_pcAJpZAxD4QAVwsgWT-9dGahon0H_oxgQx8PAB23uTrkn9PtUkupoMvt5CN-4FwLACF9HGpmqz5-j-NejQtz2F5DeIeYc4_Y1axDlsBLWuFJiNzuiJKLzYPIjT1bzpqu60</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Cox, V.</creator><creator>Furin, J.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease (IUATLD)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20171201</creationdate><title>World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?</title><author>Cox, V. ; Furin, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-dfb723f72ffbd6a02cc7643ebc78caee8e47ea6ee1c0e1784e231f62c2e2f6433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antitubercular Agents - administration & dosage</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Bedaquiline</topic><topic>Delamanid</topic><topic>Diarylquinolines - administration & dosage</topic><topic>Diarylquinolines - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug resistance</topic><topic>Drugs</topic><topic>Evaluation</topic><topic>Guidelines</topic><topic>Humans</topic><topic>Multidrug resistance</topic><topic>Multidrug resistant organisms</topic><topic>Nitroimidazoles - administration & dosage</topic><topic>Nitroimidazoles - adverse effects</topic><topic>Oxazoles - administration & dosage</topic><topic>Oxazoles - adverse effects</topic><topic>Practice Guidelines as Topic</topic><topic>Shorter Regimen</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><topic>Who</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cox, V.</creatorcontrib><creatorcontrib>Furin, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cox, V.</au><au>Furin, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>21</volume><issue>12</issue><spage>1211</spage><epage>1213</epage><pages>1211-1213</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer
drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals,
they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen.</abstract><cop>France</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>29297439</pmid><doi>10.5588/ijtld.17.0199</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2017-12, Vol.21 (12), p.1211-1213 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_pubmed_primary_29297439 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Bedaquiline Delamanid Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Drug Administration Schedule Drug resistance Drugs Evaluation Guidelines Humans Multidrug resistance Multidrug resistant organisms Nitroimidazoles - administration & dosage Nitroimidazoles - adverse effects Oxazoles - administration & dosage Oxazoles - adverse effects Practice Guidelines as Topic Shorter Regimen Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology Who World Health Organization |
| title | World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A32%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=World%20Health%20Organization%20recommendations%20for%20multidrug-resistant%20tuberculosis:%20should%20different%20standards%20be%20applied?&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Cox,%20V.&rft.date=2017-12-01&rft.volume=21&rft.issue=12&rft.spage=1211&rft.epage=1213&rft.pages=1211-1213&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.17.0199&rft_dat=%3Cpubtec_pubme%3Eiuatld/ijtld/2017/00000021/00000012/art00004%3C/pubtec_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014563525&rft_id=info:pmid/29297439&rft_ingid=iuatld/ijtld/2017/00000021/00000012/art00004&rfr_iscdi=true |